Utility of CoaguChek XS for Monitoring the Prothrombin Time

2008 ◽  
Vol 65 (6) ◽  
pp. 471 ◽  
Author(s):  
Rojin Park ◽  
Yong-Hyun Kim ◽  
Kyung Ock Kwon ◽  
Jongsung Na ◽  
Yong Soon Won ◽  
...  
Keyword(s):  
Prothrombin Time ◽  
Coaguchek Xs

scholarly journals Comparison of Prothrombin Time Derived From CoaguChek XS and Laboratory Test According to Fibrinogen Level

2014 ◽  
Vol 29 (1) ◽  
pp. 28-31 ◽  
Author(s):  
Sue Jung Kim ◽  
Eun Young Lee ◽  
Rojin Park ◽  
Juwon Kim ◽  
Jaewoo Song
Keyword(s):  
Laboratory Test ◽  
Prothrombin Time ◽  
Fibrinogen Level ◽  
Coaguchek Xs

Assessment of a portable prothrombin time analyzer (CoaguChek-XS) in dogs

2014 ◽  
Vol 24 (4) ◽  
pp. 455-460 ◽  
Author(s):  
Efrat Kelmer ◽  
Gilad Segev ◽  
Carolina Codner ◽  
Yaron Bruchim ◽  
Sigal Klainbart ◽  
...  
Keyword(s):  
Prothrombin Time ◽  
Time Analyzer ◽  
Coaguchek Xs

scholarly journals Assessment of the CoaguChek-XS portable prothrombin time point-of-care analyzer for horses

2019 ◽  
Vol 31 (3) ◽  
pp. 448-452 ◽  
Author(s):  
Noa Berlin ◽  
Efrat Kelmer ◽  
Gilad Segev ◽  
Itamar Aroch ◽  
Gal Kelmer
Keyword(s):  
Prothrombin Time ◽  
High Precision ◽  
Point Of Care ◽  
Reference Interval ◽  
Life Threatening ◽  
The Mean ◽  
Preliminary Study ◽  
Coaguchek Xs ◽  
Roche Diagnostics ◽  
Good Agreement

Coagulopathies in horses are common and potentially life-threatening. In equine field medicine, a portable point-of-care (POC) prothrombin time (PT) testing device could be useful to identify early changes in extrinsic clotting. The CoaguChek-XS (Roche Diagnostics) is a small, portable POC PT analyzer used in human medicine. Our preliminary study assessed the suitability of CoaguChek-XS for testing PT in horses and established the PT reference interval (PT RI) in healthy horses using this instrument. Blood samples collected from 102 healthy and ill horses were analyzed with the CoaguChek-XS and compared to a semi-automated coagulometric analyzer (SACA) as the gold standard. There was a significant positive correlation between the 2 measurement methods ( r = 0.765, p < 0.01), and very good agreement, with 97% of the samples falling within limits of agreement. The mean CoaguChek-XS PT coefficient of variation was 0.8%, indicating high precision. With high precision and good agreement with the coagulometric PT, the CoaguChek-XS should be further validated for PT measurement in horses.

Point-of-care monitoring of oral anticoagulation therapy in children

2009 ◽  
Vol 102 (07) ◽  
pp. 159-165 ◽  
Author(s):  
Anthea Greenway ◽  
Robyn Summerhayes ◽  
Fiona Newall ◽  
Janet Burgess ◽  
Lydia DeRosa ◽  
...  
Keyword(s):  
Prothrombin Time ◽  
Oral Anticoagulation ◽  
Gold Standard ◽  
Clinical Decision Making ◽  
Point Of Care ◽  
Anticoagulation Therapy ◽  
Clinical Decision ◽  
Gold Standard Reference ◽  
Coaguchek Xs ◽  
The Impact

SummaryPoint-of-care (POC) monitoring of oral anticoagulation has been widely adopted in both paediatric and adult patients. A new POC system, the CoaguChek XS® has recently been developed to measure the international normalised ratio (INR) and may offer significant advantages. The CoaguChek XS® utilises a new method of electrochemical clot detection based on thrombin generation. This system has not been previously evaluated in children with reference to the laboratory gold standard, the prothrombin time using reference thromboplastin. It was the objective to compare values obtained by the CoaguChek XS® system with both the venous INR and the gold standard for anticoagulant monitoring, prothrombin time with reference thromboplastin (rTF/95).To evaluate the impact of testing using the Coagu-Chek XS® on clinical anticoagulant dosing decisions. Fifty paired venous INR and capillary CoaguChek XS® results were obtained from 31 children (aged up to 16 years).The laboratory gold standard, a manual prothrombin time with reference thromboplastin (rTF/95) was additionally performed on 26 samples. Correlation between the CoaguChek XS® result and the venous INR was r= 0.810. Agreement between the CoaguChek XS result and the reference INR was shown to be higher (r=0.95), in the subset analysed by this method. Correlation between the venous INR and reference INR was r=0.90. Despite changes to the methodology of testing with the CoaguChek XS® POC monitoring system, the accuracy of this method when compared with both the venous INR and gold standard reference INR was satisfactory. This resulted in infrequent changes to clinical decision making regarding anticoagulation

Recombinant Tissue Factor as Substitute for Conventional Thromboplastin in the Prothrombin Time Test

1992 ◽  
Vol 67 (01) ◽  
pp. 042-045 ◽  
Author(s):  
Armando Tripodi ◽  
Arnaldo Arbini ◽  
Veena Chantarangkul ◽  
Pier Mannuccio Mannucci
Keyword(s):  
Prothrombin Time ◽  
Tissue Factor ◽  
Oral Anticoagulant Therapy ◽  
Clotting Factor ◽  
Rabbit Brain ◽  
Sensitivity Index ◽  
Clotting Factors ◽  
Wide Range ◽  
Reference Preparation ◽  
Time Test

SummaryRelipidated recombinant tissue factor (r-TF) has been assessed in comparison with conventional rabbit brain thromboplastin (Manchester Reagent) for its suitability for measurement of prothrombin time (PT). The International Sensitivity Index (ISI) of r-TF calibrated against the International Reference Preparation BCT/253 (human plain) was found to be 0.96 and 1.12 with instrumental and manual techniques. Our study of plasmas from patients with congenital deficiencies of clotting factors covering a wide range of severity demonstrates that r-TF is able to detect even minor deficiencies of factors involved in the extrinsic and common coagulation pathways. Patients with liver diseases were correctly diagnosed with a prevalence of abnormal results comparable for both reagents. Between-assay reproducibility expressed as coefficient of variation was 2.3 % and 3.9 % at normal and abnormal PT levels.In conclusion, our evaluation shows that relipidated r-TF possesses the necessary requisites of sensitivity, diagnostic accuracy and reproducibility which make it a suitable candidate for PT determination both for monitoring oral anticoagulant therapy and diagnosing congenital and acquired clotting factor deficiencies. Moreover, being a highly defined reagent it may constitute a step forward in the standardization of PT testing.

Sign in / Sign up

Export Citation Format

Share Document